Skip to main content
. Author manuscript; available in PMC: 2021 Aug 6.
Published in final edited form as: Neuropharmacology. 2020 Dec 28;185:108445. doi: 10.1016/j.neuropharm.2020.108445

Fig. 4.

Fig. 4.

Chronic administration of MP1104 and morphine in chemotherapy-treated C57BL/6J mice. (A) Experimental design for chronic treatment of MP1104 or morphine in mice with established paclitaxel-induced neuropathic pain. MP1104 (1.2 mg/kg) and morphine (10 mg/kg) daily i.p. injections reduced paclitaxel-induced (B–C) mechanical and (D–E) cold allodynia. MP1104 completely restored mechanical threshold and cold allodynia to non-diseased levels. The area under the curve (AUC) showed morphine and MP1104 reduced (C) mechanical and (E) cold allodynia compared to the vehicle/paclitaxel group. Two-way ANOVA with Bonferroni post-tests; vehicle/vehicle, MP1104 and morphine *p < 0.05, ****p < 0.0001 compared to the vehicle/paclitaxel control treatment group. Values expressed as mean ± SEM, n = 9. Ptx, paclitaxel; Veh, vehicle.